A Malaria Vaccine Based on CH-rPfs 48/45 Antigen and Adjuvant Formulations to Stop Malaria Transmission

Case ID:

C10497

C10497: A Malaria Vaccine to Stop Malaria Transmission
Technical Details:
Malaria is a disease caused by parasites of the genus Plasmodium. It affects near 2 billion people worldwide and results in 1-2 million deaths every year. Transmission-blocking vaccines (TBV) have received attention as potentially effective strategy in the fight against malaria. Surface antigens have been identified as candidates for the development of TBVs. However, efforts to produce properly folded recombinant form of full length of antigens have not been so fruitful. This invention uses a new cloning strategy to obtain the protein in immunologically active conformation, which produced high titer antibodies. These antibodies exhibited nearly complete blocking of malaria transmission when tested in mosquito membrane feeding assay. This invention provides the proof-of-concept that adjuvant formulation can now be developed into a malaria vaccine to stop and/or reduce malaria transmission by vaccination.
Looking for Partners:
Development of malaria transmission-blocking vaccine

Direct Link:

https://jhu.technologypublisher.com/technology/16680

Inventors:

Category(s):

Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Infectious Diseases,

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Vera Sampels

vsampel2@jhu.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF